Quanbeck Andrew, Johnson Roberta A, Saha-Muldowney Mondira, Resnik Felice, Hirschfield Sheena, Meline Rachael R, Mahoney Jane E
D & I (Dissemination and Implementation) Launchpad, Institute for Clinical and Translational Research, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA.
Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, USA.
J Clin Transl Sci. 2021 Jul 26;5(1):e160. doi: 10.1017/cts.2021.828. eCollection 2021.
BACKGROUND/OBJECTIVE: Although most research universities offer investigators help in obtaining patents for inventions, investigators generally have few resources for scaling up non-patentable innovations, such as health behavior change interventions. In 2017, the dissemination and implementation (D & I) team at the University of Wisconsin's Clinical and Translational Science Award (CTSA) created the Evidence-to-Implementation (E2I) award to encourage the scale-up of proven, non-patentable health interventions. The award was intended to give investigators financial support and business expertise to prepare evidence-based interventions for scale-up.
The D & I team adapted a set of criteria named Critical Factors Assessment, which has proven effective in predicting the success of entrepreneurial ventures outside the health care environment, to use as review criteria for the program. In March 2018 and February 2020, multidisciplinary panels assessed proposals using a review process loosely based on the one used by the NIH for grant proposals, replacing the traditional NIH scoring criteria with the eight predictive factors included in Critical Factors Assessment.
two applications in 2018 and three applications in 2020 earned awards. Funding has ended for the first two awardees, and both innovations have advanced successfully.
Late-stage translation, though often overlooked by the academic community, is essential to maximizing the overall impact of the science generated by CTSAs. The Evidence-to-implementation award provides a working model for supporting late-stage translation within a CTSA environment.
背景/目的:尽管大多数研究型大学会为研究人员提供发明获得专利方面的帮助,但研究人员通常缺乏资源来扩大非专利创新的规模,比如健康行为改变干预措施。2017年,威斯康星大学临床与转化科学奖(CTSA)的传播与实施(D&I)团队设立了循证实施(E2I)奖,以鼓励扩大已证实的、非专利健康干预措施的规模。该奖项旨在为研究人员提供资金支持和商业专业知识,以便为扩大规模准备基于证据的干预措施。
D&I团队采用了一套名为关键因素评估的标准,该标准已被证明在预测医疗保健环境之外的创业企业成功方面有效,将其用作该项目的评审标准。2018年3月和2020年2月,多学科评审小组采用了一个大致基于美国国立卫生研究院(NIH)资助申请评审流程的评审程序来评估提案,用关键因素评估中包含的八个预测因素取代了传统的NIH评分标准。
2018年有两项申请、2020年有三项申请获得了奖项。前两位获奖者的资金已经结束,两项创新都取得了成功进展。
后期转化虽然常常被学术界忽视,但对于使CTSA产生的科学的整体影响最大化至关重要。循证实施奖为在CTSA环境中支持后期转化提供了一个可行的模式。